Intravitreal anti-vegf drugs as adjuvant therapy in diabetic retinopathy surgery

Current Diabetes Reviews

Volumn 7, Issue 3, 2011, Pages 176-184

  Montero, Javier A ^a,b   Ruiz Moreno, José Ma ^b,c   Correa, Maria E ^a  

^a HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^b Vitreo Retinal Unit   (Spain)

^c UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

Author keywords

Bevacizumab; Bevasiranib; Diabetic macular edema; Diabetic retinopathy; Glaucoma surgery; Laser photocoagulation; Pegaptanib; Phacoemulsification; Proliferative diabetic retinopathy; Ranibizumab; Vegf; Vegf trap; Vitrectomy

Indexed keywords

BEVACIZUMAB; BEVASIRANIB; EFALIZUMAB; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE; VASCULOTROPIN A;

ADJUVANT THERAPY; CLINICAL TRIAL; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG MEGADOSE; GLAUCOMA SURGERY; HUMAN; LASER COAGULATION; LOW LEVEL LASER THERAPY; NEOVASCULAR GLAUCOMA; NEOVASCULARIZATION (PATHOLOGY); PHACOEMULSIFICATION; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA CYSTOID EDEMA; RETINA SURGERY; REVIEW; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VITREOUS HEMORRHAGE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; APTAMERS, NUCLEOTIDE; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DIABETIC RETINOPATHY; HUMANS; INTRAVITREAL INJECTIONS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITRECTOMY;

EID: 79959339406     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/157339911795843104     Document Type: Review

References (87)

1. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol 2007; 14: 179-83.
2. Paulus YM, Gariano RF. Diabetic retinopathy: a growing concern in an aging population. Geriatrics 2009; 64: 16-20.
3. Prahs P, Helbig H. [Diabetic eye disease]. Ther Umsch 2009; 66: 183-8.
4. Aaberg TM, Abrams GW. Changing indications and techniques for vitrectomy in management of complications of diabetic retinopathy. Ophthalmology 1987; 94: 775-9.
5. Cury CE, Jr., Rodrigues EB, Meyer CH, Farah ME. VEGF inhibitors and vitrectomy for diabetic vitreoretinopathy. Dev Ophthalmol 2009; 44: 69-81.
6. Zhang X, Bao S, Hambly BD, Gillies MC. Vascular endothelial growth factor-A: a multifunctional molecular player in diabetic retinopathy. Int J Biochem Cell Biol 2009; 41: 2368-71.
7. Danis RP, Ciulla TA, Criswell M, Pratt L. Anti-angiogenic therapy of proliferative diabetic retinopathy. Expert Opin Pharmacother 2001; 2: 395-407.
8. Lebherz C, Maguire AM, Auricchio A, et al. Nonhuman primate models for diabetic ocular neovascularization using AAV2- mediated overexpression of vascular endothelial growth factor. Diabetes 2005; 54: 1141-9.
9. Hattori T, Shimada H, Nakashizuka H, et al. Dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy. Retina 2010; 30: 761-4.
10. Kuo YR, Wang CT, Wang FS, Chiang YC, Wang CJ. Extracorporeal shock-wave therapy enhanced wound healing via increasing topical blood perfusion and tissue regeneration in a rat model of STZ-induced diabetes. Wound Repair Regen 2009; 17: 522-30.
11. Funatsu H, Yamashita H, Noma H, et al. Prediction of macular edema exacerbation after phacoemulsification in patients with nonproliferative diabetic retinopathy. J Cataract Refract Surg 2002; 28: 1355.
12. Hartnett ME, Tinkham N, Paynter L, et al. Aqueous vascular endothelial growth factor as a predictor of macular thickening following cataract surgery in patients with diabetes mellitus. Am J Ophthalmol 2009; 148: 895-901. e1.
13. Shimada H, Akaza E, Yuzawa M, Kawashima M. Concentration gradient of vascular endothelial growth factor in the vitreous of eyes with diabetic macular edema. Invest Ophthalmol Vis Sci 2009; 50: 2953-5.
14. Funatsu H, Yamashita H, Noma H, et al. Risk evaluation of outcome of vitreous surgery for proliferative diabetic retinopathy based on vitreous level of vascular endothelial growth factor and angiotensin II. Br J Ophthalmol 2004; 88: 1064-8.
15. Kobayashi T, Machida S, Fujiwara T, Ishibe T, Kurosaka D. Vitreous levels of vascular endothelial growth factor in eyes with anterior hyaloidal fibrovascular proliferation. Clin Ophthalmol 2010; 4: 1043-6.
16. Chung EJ, Kang SJ, Koo JS, et al. Effect of intravitreal bevacizumab on vascular endothelial growth factor expression in patients with proliferative diabetic retinopathy. Yonsei Med J 2010; 52: 151-7.
17. Sawada O, Kawamura H, Kakinoki M, Sawada T, Ohji M. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol 2007; 125: 1363-6.
18. Ishida S, Usui T, Yamashiro K. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemiainduced retinal neovascularization. J Exp Med Arch 2003: 483-9.
19. Ishida S, Usui T, Yamashiro K. VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 2003; 44: 2155-62.
20. Cunningham ET Jr., Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112: 1747-57.
21. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
22. Yoganathan P, Deramo VA, Lai JC, Tibrewala RK, Fastenberg DM. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 2006; 26: 994-8.
23. Beutel J, Ziemssen F, Luke M, et al. Intravitreal bevacizumab treatment of macular edema in central retinal vein occlusion: oneyear results. Int Ophthalmol 2010; 30: 15-22.
24. Jaissle GB, Leitritz M, Gelisken F, et al. One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2009; 247: 27-33.
25. Spaide RF, Chang LK, Klancnik JM, et al. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 2009; 147: 298-306.
26. Beutel J, Peters S, Luke M, et al. Bevacizumab as adjuvant for neovascular glaucoma. Acta Ophthalmol 2010; 88: 103-9.
27. Ishibashi S, Tawara A, Sohma R, Kubota T, Toh N. Angiographic changes in iris and iridocorneal angle neovascularization after intravitreal bevacizumab injection. Arch Ophthalmol 2010; 128: 1539-45.
28. Alvarez Y, Astudillo O, Jensen L, et al. Selective inhibition of retinal angiogenesis by targeting PI3 kinase. PLoS One 2009; 4: e7867.
29. Kubota T, Morita H, Tou N, et al. Histology of fibrovascular membranes of proliferative diabetic retinopathy after intravitreal injection of bevacizumab. Retina 2010; 30: 468-72.
30. Kohno R, Hata Y, Mochizuki Y, et al. Histopathology of neovascular tissue from eyes with proliferative diabetic retinopathy after intravitreal bevacizumab injection. Am J Ophthalmol 2010; 150: 223-229 e1.
31. Mendrinos E, Donati G, Pournaras CJ. Rapid and persistent regression of severe new vessels on the disc in proliferative diabetic retinopathy after a single intravitreal injection of pegaptanib. Acta Ophthalmol 2009; 87: 683-4.
32. Adamis AP, Altaweel M, Bressler NM, et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006; 113: 23-8.
33. Gonzalez VH, Giuliari GP, Banda RM, Guel DA. Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy. Br J Ophthalmol 2009; 93: 1474-8.
34. Shin YW, Lee YJ, Lee BR, Cho HY. Effects of an intravitreal bevacizumab injection combined with panretinal photocoagulation on high-risk proliferative diabetic retinopathy. Korean J Ophthalmol 2009; 23: 266-72.
35. Tonello M, Costa RA, Almeida FP, et al. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol 2008; 86: 385-9.
36. Mirshahi A, Roohipoor R, Lashay A, et al. Bevacizumabaugmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial. Eur J Ophthalmol 2008; 18: 263-9.
37. Batman C, Ozdamar Y. The relation between bevacizumab injection and the formation of subretinal fibrosis in diabetic patients with panretinal photocoagulation. Ophthalmic Surg Lasers Imaging 2010; 41: 190-5.
38. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985; 103: 1796-806.
39. Querques G, Bux AV, Martinelli D, Iaculli C, Noci ND. Intravitreal pegaptanib sodium (Macugen) for diabetic macular oedema. Acta Ophthalmol 2009; 87: 623-30.
40. Nguyen QD, Shah SM, Heier JS, et al. Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2009; 116: 2175-81. e1.
41. Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2010; 117: 2146-51.
42. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117: 1064-1077. e35.
43. Goyal S, Lavalley M, Subramanian ML. Meta-analysis and review on the effect of bevacizumab in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2011; 249: 15-27.
44. Arevalo JF, Sanchez JG, Wu L, et al. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology 2009; 116: 1488-97, 1497 e1.
45. Kumar A, Sinha S. Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population. Indian J Ophthalmol 2007; 55: 451-5.
46. Faghihi H, Roohipoor R, Mohammadi SF, et al. Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol 2008; 18: 941-8.
47. Moreno-Lopez M, Regueras A. [Intravitreal bevacizumab followed by focal laser for diffuse diabetic macular edema of recent progression. A clinical case]. Arch Soc Esp Oftalmol 2009; 84: 209-12.
48. Scott IU, Edwards AR, Beck RW, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007; 114: 1860-7.
49. Soheilian M, Ramezani A, Bijanzadeh B, et al. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina 2007; 27: 1187-95.
50. Robaszkiewicz J, Chmielewska K, Wierzbowska J, et al. [Combined surgical and pharmacological treatment of diabetic maculopathy]. Klin Oczna 2010; 112: 19-23.
51. Arevalo JF, Maia M, Flynn HW Jr., et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 2008; 92: 213-6.
52. Huang YH, Yeh PT, Chen MS, Yang CH, Yang CM. Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage. Retina 2009; 29: 1134-40.
53. Montero JA, Ruiz-Moreno JM, De La Vega C. Incomplete posterior hyaloid detachment after intravitreal pegaptanib injection in diabetic macular edema. Eur J Ophthalmol 2008; 18: 469-72.
54. Rouvas A, Petrou P, Ladas I, Neamonitou G, Vergados I. Spontaneous resolution of vitreomacular traction following ranibizumab (Lucentis) injection. Eur J Ophthalmol 2008; 18: 301-3.
55. Helbig H, Kellner U, Bornfeld N, Foerster MH. [Vitrectomy in diabetic retinopathy: outcome, risk factors, complications]. Klin Monbl Augenheilkd 1998; 212: 339-42.
56. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113: 1695 e1-15.
57. Ishikawa K, Honda S, Tsukahara Y, Negi A. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye (Lond) 2009; 23: 108-11.
58. Di Lauro R, De Ruggiero P, Di Lauro R, Di Lauro MT, Romano MR. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010; 248: 785-91.
59. Modarres M, Nazari H, Falavarjani KG, et al. Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy. Eur J Ophthalmol 2009; 19: 848-52.
60. Rizzo S, Genovesi-Ebert F, Di Bartolo E, et al. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol 2008; 246: 837-42.
61. Yeoh J, Williams C, Allen P, et al. Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series. Clin Experiment Ophthalmol 2008; 36: 449-54.
62. Yeh PT, Yang CM, Lin YC, Chen MS, Yang CH. Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy. Retina 2009; 29: 768-74.
63. Ahmadieh H, Shoeibi N, Entezari M, Monshizadeh R. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. Ophthalmology 2009; 116: 1943-8.
64. Hernandez-Da Mota SE, Nunez-Solorio SM. Experience with intravitreal bevacizumab as a preoperative adjunct in 23-G vitrectomy for advanced proliferative diabetic retinopathy. Eur J Ophthalmol 2010; 20: 1047-52.
65. Oshima Y, Shima C, Wakabayashi T, et al. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology 2009; 116: 927-38.
66. Da RLD, Ribeiro JA, Costa RA, et al. Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study). Br J Ophthalmol 2009; 93: 688-91.
67. Schachat AP, Oyakawa RT, Michels RG, Rice TA. Complications of vitreous surgery for diabetic retinopathy. II. Postoperative complications. Ophthalmology 1983; 90: 522-30.
68. Cooper B, Shah GK, Grand MG, Bakal J, Sharma S. Visual outcomes and complications after multiple vitrectomies for diabetic vitreous hemorrhage. Retina 2004; 24: 19-22.
69. Ruiz-Moreno JM, Montero JA, Lugo F, Amat P, Staicu C. Intravitreal bevacizumab in recurrent diabetic vitreous haemorrhage after vitrectomy. Acta Ophthalmol 2008; 86: 231-2.
70. Sawa H, Ikeda T, Matsumoto Y, Niiya A, Kinoshita S. [Neovascularization from the scleral wound as the cause of vitreous rebleeding after vitrectomy for proliferative diabetic retinopathy]. Nippon Ganka Gakkai Zasshi 1998; 102: 200-6.
71. Yang CM, Yeh PT, Yang CH, Chen MS. Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy. Am J Ophthalmol 2008; 146: 211-217.
72. Lo WR, Kim SJ, Aaberg TM, Sr., et al. Visual outcomes and incidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bevacizumab (avastin). Retina 2009; 29: 926-31.
73. Arevalo JF, Sanchez JG, Lasave AF, et al. Intravitreal Bevacizumab (Avastin(R)) for Diabetic Retinopathy at 24-months: The 2008 Juan Verdaguer-Planas Lecture. Curr Diabetes Rev 2010; 6: 313-22.
74. Lee SJ, Koh HJ. Enlargement of the foveal avascular zone in diabetic retinopathy after adjunctive intravitreal bevacizumab (avastin) with pars plana vitrectomy. J Ocul Pharmacol Ther 2009; 25: 173-4.
75. Chen E, Hsu J, Park CH. Acute visual acuity loss following intravitreal bevacizumab for diabetic macular edema. Ophthalmic Surg Lasers Imaging 2009; 40: 68-70.
76. Takamura Y, Kubo E, Akagi Y. Analysis of the effect of intravitreal bevacizumab injection on diabetic macular edema after cataract surgery. Ophthalmology 2009; 116: 1151-7.
77. Lanzagorta-Aresti A, Palacios-Pozo E, Menezo Rozalen JL, Navea-Tejerina A. Prevention of vision loss after cataract surgery in diabetic macular edema with intravitreal bevacizumab: a pilot study. Retina 2009; 29: 530-5.
78. Chen CH, Liu YC, Wu PC. The combination of intravitreal bevacizumab and phacoemulsification surgery in patients with cataract and coexisting diabetic macular edema. J Ocul Pharmacol Ther 2009; 25: 83-9.
79. Akinci A, Batman C, Ozkilic E, Altinsoy A. Phacoemulsification with intravitreal bevacizumab injection in diabetic patients with macular edema and cataract. Retina 2009; 29: 1432-5.
80. Spitzer MS, Ziemssen F, Yoeruek E, et al. Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema. J Cataract Refract Surg 2008; 34: 70-5.
81. Hasanreisoglu M, Weinberger D, Mimouni K, et al. Intravitreal bevacizumab as an adjunct treatment for neovascular glaucoma. Eur J Ophthalmol 2009; 19: 607-12.
82. Gupta V, Jha R, Rao A, Kong G, Sihota R. The effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma. Eur J Ophthalmol 2009; 19: 435-41.
83. Wasik A, Song HF, Grimes A, Engelke C, Thomas A. Bevacizumab in conjunction with panretinal photocoagulation for neovascular glaucoma. Optometry 2009; 80: 243-8.
84. Ciftci S, Sakalar YB, Unlu K, et al. Intravitreal bevacizumab combined with panretinal photocoagulation in the treatment of open angle neovascular glaucoma. Eur J Ophthalmol 2009; 19: 1028-33.
85. Vasudev D, Blair MP, Galasso J, Kapur R, Vajaranant T. Intravitreal bevacizumab for neovascular glaucoma. J Ocul Pharmacol Ther 2009; 25: 453-8.
86. Douat J, Auriol S, Mahieu-Durringer L, et al. [Intravitreal bevacizumab for treatment of neovascular glaucoma. Report of 20 cases]. J Fr Ophtalmol 2009; 32: 652-63.
87. Sothornwit N. Intravitreal bevacizumab for ahmed glaucoma valve implantation in neovascular glaucoma: a case report. J Med Assoc Thai 2008; 91(Suppl 1): S162-5.